Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Eligible age
6+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.
Sponsor: Arcutis Biotherapeutics, Inc.
You may qualify if…
- ✓ 1. Male or female participants aged 6 years and older.
- ✓ 2. Clinical diagnosis of moderate to severe atopic dermatitis.
- ✓ 3. vIGA-AD score of 3 (Moderate) or 4 (Severe) at baseline.
- ✓ 4. EASI score ≥5 at baseline.
- ✓ 5. Atopic dermatitis involvement of ≥3% and ≤30% body surface area.
- ✓ 6. Able and willing to comply with study procedures.
- ✓ 7. Participant or parent/legal guardian able to provide informed consent/assent.
You may not qualify if…
- ✕ 1. Uncontrolled medical conditions that could interfere with study participation.
- ✕ 2. Skin disorders that may confound study assessments.
- ✕ 3. Active infection requiring systemic treatment.
- ✕ 4. Known hypersensitivity to roflumilast or formulation components.
- ✕ 5. Use of prohibited medications within protocol-defined washout periods.
- ✕ 6. Pregnant or breastfeeding participants.
- ✕ 7. Participation in another interventional clinical trial within the protocol-defined timeframe.
- ✕ 8. Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study results.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07916480 · last updated 2026-11-06